Immunic Inc
IMUX
Get informed when a big investor buys or sells
+ FollowMarket Cap$194.79M
Close$
$9.51
42.7% downside
Current Fair Value
42.7% downsideOvervalued by 42.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $194.79 Million |
|---|---|
| Enterprise Value | $40.26 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.24 |
| Beta | 1.38 |
| Outstanding Shares | 3,013,632 |
Return
| Return on Equity | -87.45% |
|---|---|
| Return on Assets | -70.09% |
| Return on Invested Capital | -87.73% |
Valuation & Multiples
| P/E Ratio | -2.39 |
|---|---|
| PEG | -8.81 |
| Price to Sales | - |
| Price to Book Ratio | 0.39 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.36 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-1.16
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.06
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2217▼ 2.62% |
|---|---|
| Total Calls | 302,700▲ 85.25% |
| Total Puts | 67,100▲ 65.68% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 21.22%▼ 11.71% |
|---|---|
| Total Invested | $71.00M▲ 151.26% |
| Investors Holding | 80▲ 17.00% |
ESG Score
No data
About Immunic Inc
28 employees
CEO: Daniel Vitt Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerati...